Europac
EUROPAC, the European Registry of Hereditary Pancreatic Diseases, is the world’s biggest study into hereditary pancreatic diseases and is co-ordinated in Liverpool.
Description
The study maintain a register of families in whom there is thought to be an increased risk of pancreatic cancer. Studies have shown that an increased risk of cancer is inferred if two or more first-degree relatives have the condition.
The study is supported by grants from Cancer Research UK, The European Union, the National Institute for Health Research (NIHR) and Pancreatic Cancer UK.
In addition to the Familial Pancreatic Cancer (FPC) registry, EUROPAC offer screening for early pancreatic cancer on a research basis in those deemed at high risk for development of the condition. Screening for early pancreatic cancer involves a number of different blood tests and scans and is usually undertaken from the age of 40 in high-risk individuals.
Patients who have a family history of pancreatic cancer or pancreatitis may be eligible to join the study. Referrals are made via genetic counsellors, GPs, other consultants or directly via email.
The research team based in Liverpool includes Annabelle Boughey (EUROPAC Coordinator), Phil Hopley (clinical research fellow), Professor Christoper Halloran (principal investigator) and Professor William Greenhalf (lead scientist).
Further information about the study can be found on the study website: https://www.europactrial.com/